Boston Scientific leads a five-company, $19.42M insider-buy week (2026)

Five US-listed companies cleared the channel’s strict screen for officer or director open-market purchases above $1 million during the Aug. 3–10 window. The clean total was $19.42 million, led by Boston Scientific CEO Michael Mahoney’s $9.00 million purchase and Aptiv director Paul Meister’s $5.00 million buy.

The useful distinction this week is not simply size. One large-looking cluster matched a fresh IPO price and is excluded; another apparent seven-figure Form 4 was filed inside the window but traded before it began. The five names below are the transactions that survived those checks.

Screen window: Aug. 3, 2026 at 08:00 through Aug. 10, 2026 at 08:00 ET Eligibility: officer/director, Form 4 code P, more than $1 million per transaction or in combined purchases by the same insider during the window Important caveat: code P identifies a purchase of securities, but it does not by itself prove a public-exchange execution. Financing-linked, IPO-price, plan-based, and otherwise ambiguous rows were held out where the filing or issuer context did not support a discretionary open-market reading.

The five clean signals

Company	Insider and role	Purchase	Latest mark	Market cap	Sector / industry	What to notice
Boston Scientific (BSX)	Michael F. Mahoney, chairman, president and CEO	186,240 shares at a weighted average $48.3323; $9.001M 1	$49.52, about +2.5% from the reported average 2	$71.77B 2	Healthcare / Medical Devices	Two directors also bought small amounts in the same week; not a second seven-figure signal.
Aptiv (APTV)	Paul M. Meister, director; purchase held through a trust	105,631 ordinary shares at $47.3342; $4.999959M 3	$49.30, about +4.2% 4	$10.24B 4	Consumer Cyclical / Auto Parts	Indirect ownership, but the filing’s P code is not marked as a 10b5-1 trade.
CoStar Group (CSGP)	Andrew C. Florance, founder and CEO	83,300 shares at $29.89; $2.490M 5	$30.55, about +2.2% 6	$12.38B 6	Real Estate / Real Estate Services	This was another large Florance purchase after earlier 2026 buys at materially higher prices.
American Bitcoin (ABTC)	Justin Mateen, director	306,981 shares across Aug. 5–6; $1.930M combined, at weighted averages of $6.3964 and $6.1873 7	$6.99, about +11.2% versus the combined weighted average 8	$509.01M 8	Financial / Capital Markets	The Form 4 says the purchases were not made under a 10b5-1 plan; share counts reflect the July 2 reverse split.
Ingersoll Rand (IR)	Aurobind Satpathy, director	11,538 shares at a weighted average $86.678; $1.000091M 9	$86.97, about +0.3% 10	$33.74B 10	Industrials / Specialty Industrial Machinery	A narrow pass over the threshold; the filing gives a price range of $86.649–$86.70.

The marks above are simple comparisons with the latest quote snapshot available on Aug. 10. They are not six- or twelve-month returns, and they do not adjust for dividends, corporate actions, or trading costs.

1. BSX: the largest clean purchase, after a strong quarter but lower full-year guidance

Mahoney’s Form 4 reports 186,240 Boston Scientific common shares bought on Aug. 3 at a weighted average of $48.3323, with individual executions between $47.87 and $48.47. The filing does not mark the Rule 10b5-1 plan box. It also reports a separate 22,119-share indirect acquisition through the company’s 401(k) plan; the $9.001 million screen value above is the direct purchase only. 11

The timing followed Boston Scientific’s July 29 second-quarter release. Q2 sales were $5.442 billion, up 7.5% reported, and adjusted EPS was $0.86 versus a $0.82–$0.84 guidance range. The offset is the company’s lower full-year outlook: reported sales growth was reset to 5.5%–6.5%, with adjusted EPS guidance of $3.28–$3.32. 12

That gives the purchase a clear, mixed backdrop: quarterly execution was better than the near-term target, while the annual growth outlook was cut. It is context, not proof that Mahoney was responding to one particular headline.

Track record and cluster. The captured BSX issuer history shows no earlier open-market purchase by Mahoney to use as a performance sample. It does show director David Habiger buying 1,182 shares on Aug. 3 and another 2,100 on Aug. 5, worth roughly $156,800 combined. That is a same-week director cluster, but it is supporting evidence rather than a second threshold-clearing signal. 13

2. APTV: a $5M director purchase held through a trust

Meister’s Form 4 records 105,631 Aptiv ordinary shares bought on Aug. 5 at $47.3342 through the Woburn Abbey March 2021 Trust GST Exempt Share. The filing reports indirect ownership, code P, and no affirmative 10b5-1 indication. 14

The purchase arrived one day after Aptiv reported Q2 results. The company reported $3.274 billion of quarterly revenue and $1.63 of adjusted EPS, while lowering full-year 2026 guidance to $12.6–$12.8 billion of net sales, $5.60–$5.80 of adjusted EPS, and $625–$725 million of free cash flow. 15

The signal is therefore easy to frame but not easy to score: a director put nearly $5 million into the stock immediately after results that showed higher quarterly earnings but a lower annual outlook. The trust structure matters for ownership analysis, but it does not turn the transaction into an executive operating purchase.

Track record. The Aptiv issuer page used for this screen did not show an earlier purchase by Meister, so there is no prior-buy sample here to test for six- or twelve-month follow-through. The latest mark is modestly above the reported average, but that is only an initial mark-to-market observation.

3. CSGP: Florance keeps buying into a lower price

CoStar founder and CEO Florance bought 83,300 shares on Aug. 4 at an average of $29.89, with the Form 4 footnote placing the executions between $29.57 and $29.99. The filing does not indicate a Rule 10b5-1 plan. 16

The company had just reported Q2 revenue of $925 million and net income of $55 million. Its quarterly filing also disclosed an agreement to acquire Zonda for $800 million in cash, subject to closing conditions. 17 That is the relevant company backdrop in the two-week check around the purchase; it does not establish that the acquisition caused the buy.

Track record. Florance’s prior purchases provide more history than most names in this week’s screen:

May 1, 2026: 71,430 shares at $35.20, or $2.514 million.
Feb. 27, 2026: 55,720 shares at $44.52, or $2.481 million.
Oct. 25, 2024: 14,731 shares at $74.67, or about $1.100 million.

At the latest $30.55 mark, those earlier entries are down approximately 13%, 31%, and 59%, respectively. These are current-price comparisons rather than aligned six- or twelve-month event windows, but they do not show a history of immediate price appreciation after the buys. 18

4. ABTC: a two-day director buy with a live earnings catalyst

Mateen’s Form 4 covers 144,543 American Bitcoin Class A shares bought on Aug. 5 at a weighted average $6.3964 and 162,438 bought on Aug. 6 at $6.1873. Together they total 306,981 shares and $1.930 million. The filing says the transactions were code P, not made pursuant to a 10b5-1 plan, and adjusted for the company’s July 2 1-for-15 reverse split. 19

The company released Q2 results on Aug. 3, before the two purchases. Revenue was $67.0 million, the company mined about 932 bitcoin, and reported reserves of about 8,002 bitcoin as of June 30. The quarter still produced a $57.2 million net loss. 20

That combination matters for judgment: Mateen bought after a record-production update, but the business remained loss-making. The latest $6.99 mark is about 11% above the combined weighted average, though the period is too short to treat that as validation.

Track record and cluster. No earlier Mateen open-market purchase was available in the issuer history captured for this screen, so there is no established six- or twelve-month track record to report. This is one insider buying over two consecutive sessions, not a multi-insider cluster.

5. IR: a threshold-edge purchase after raised guidance

Satpathy bought 11,538 Ingersoll Rand common shares on Aug. 3 at a weighted average $86.678. The filing identifies code P and an open-market purchase, with individual prices from $86.649 to $86.70. The reported gross value was $1,000,091—just $91 above the screen threshold. 21

The company had reported Q2 results on July 30: revenue of $2.049 billion, adjusted EBITDA of $519.9 million, and full-year 2026 revenue-growth guidance of 4.5%–6.5%. Adjusted EPS guidance was $3.45–$3.57. 22

The purchase therefore followed a results-and-guidance update that was stronger than the prior-year comparison, but its size is best read literally: it is a marginal pass, not a $10 million conviction signal.

Track record. The available issuer history did not show an earlier open-market purchase by Satpathy. The latest mark is only about 0.3% above the reported average, which is effectively noise at this horizon.

What did not count

TM: code P, but the venue is not resolved

Toyota president and director Kenta Kon reported 85,000 common shares bought on Aug. 5 at a USD-converted price of $18.41, worth about $1.565 million. The Form 4 says the purchase was made in Japanese yen and describes the venue as “open-market or private”; it also says the trade was not under a 10b5-1 plan. 23

That ambiguity is enough to keep TM out of the clean total. The filing price is for Toyota common stock converted from yen, while the U.S. quote is an ADR mark; I do not compare the raw $18.41 filing price with the $188.68 ADR quote. Toyota also released FY2027 first-quarter results on Aug. 4, reporting 13.525 trillion yen of sales revenue and revising its full-year net-income forecast to 3.25 trillion yen. 24 The company context is material, but it does not cure the filing’s unresolved execution venue.

BRVE: an IPO-price cluster, not an open-market conviction signal

Braveheart Bio’s CEO Travis Murdoch and director Christopher Viehbacher each reported roughly $1.50 million of code-P purchases on Aug. 7 at exactly $18.00 per share. A separate 10% holder reported a $64.8 million purchase at the same price. 25 26

The issuer had priced its upsized IPO at $18 on Aug. 5, with trading expected to begin Aug. 6 and closing expected Aug. 7. The exact price match and timing make these rows financing-linked for this screen, even though the Form 4 parser labels them P. 27

Other large rows

The weekly insider list also contained purchases by 10% holders, sponsor entities, funds, acquisition companies, and other non-officer/non-director entities. Those are outside this channel’s officer/director scope. A Form 4 row filed on Aug. 10 for 51Talk CEO Jack Huang was also held out: OpenInsider shows the trade date as July 31, before this screen opened. 28

Bottom line

The clean list is unusually concentrated: $14.00 million, or about 72% of the total, came from two purchases at BSX and APTV, both shortly after quarterly updates that combined solid current results with some forward-looking caution. CSGP offers the most developed insider history, but its earlier Florance purchases are underwater at the current mark. ABTC has a clear two-day, non-plan director buy after a record-production quarter, while IR just clears the threshold.

These are signals for further work, not stand-alone buy calls. The next useful checks are the companies’ valuation, balance-sheet risk, and whether the post-filing price action persists beyond the first few sessions.